Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (975) 975
Newsletter (65) 65
Book Chapter (19) 19
Newspaper Article (16) 16
Magazine Article (6) 6
Conference Proceeding (4) 4
Dissertation (3) 3
Publication (2) 2
Streaming Video (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pazopanib (1071) 1071
science & technology (600) 600
life sciences & biomedicine (592) 592
humans (424) 424
oncology (405) 405
metastasis (237) 237
female (220) 220
research (217) 217
cancer (207) 207
care and treatment (206) 206
male (204) 204
pyrimidines - therapeutic use (181) 181
middle aged (180) 180
sulfonamides - therapeutic use (179) 179
sunitinib (172) 172
aged (170) 170
drug therapy (170) 170
sarcoma (167) 167
renal cell carcinoma (151) 151
adult (142) 142
pharmacology & pharmacy (142) 142
carcinoma, renal cell (138) 138
chemotherapy (134) 134
tumors (134) 134
angiogenesis inhibitors (131) 131
carcinoma, renal cell - drug therapy (131) 131
vascular endothelial growth factor (126) 126
kidney neoplasms - drug therapy (125) 125
sorafenib (118) 118
pyrimidines - adverse effects (116) 116
angiogenesis inhibitors - therapeutic use (115) 115
sulfonamides - adverse effects (115) 115
treatment outcome (112) 112
pyrimidines - administration & dosage (109) 109
sulfonamides - administration & dosage (109) 109
analysis (102) 102
antineoplastic agents - therapeutic use (102) 102
health aspects (100) 100
dosage and administration (99) 99
patients (99) 99
medicine & public health (96) 96
tyrosine (93) 93
bevacizumab (92) 92
angiogenesis (91) 91
clinical trials (84) 84
kidney cancer (83) 83
physical fitness (81) 81
aged, 80 and over (80) 80
kidney neoplasms - pathology (77) 77
patient outcomes (77) 77
prognosis (75) 75
case report (74) 74
antineoplastic agents (73) 73
axitinib (72) 72
pyrimidines - pharmacology (72) 72
soft tissue sarcoma (72) 72
complications and side effects (71) 71
disease-free survival (71) 71
animals (69) 69
sulfonamides - pharmacology (69) 69
development and progression (67) 67
protein kinase inhibitors - therapeutic use (67) 67
angiogenesis inhibitors - adverse effects (66) 66
biological and medical sciences (66) 66
medical sciences (65) 65
metastases (63) 63
neoplasms. tumors. oncology. including cancer and carcinogens (63) 63
tyrosine kinase inhibitor (61) 61
retrospective studies (57) 57
tyrosine kinase inhibitors (57) 57
urology & nephrology (56) 56
carcinoma, renal cell - pathology (55) 55
medical research (55) 55
cancer therapies (53) 53
young adult (52) 52
antimitotic agents (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (51) 51
hematology, oncology and palliative medicine (51) 51
neoplasm metastasis (49) 49
sarcoma - drug therapy (49) 49
antineoplastic agents - adverse effects (48) 48
targeted therapy (48) 48
everolimus (47) 47
neoplasms - drug therapy (47) 47
usage (47) 47
cancer research (46) 46
hypertension (46) 46
pharmacology/toxicology (46) 46
immunotherapy (45) 45
medicine, experimental (45) 45
ovarian cancer (45) 45
receptors, vascular endothelial growth factor - antagonists & inhibitors (44) 44
dose-response relationship, drug (42) 42
medical prognosis (42) 42
risk factors (42) 42
kinases (41) 41
oncology, experimental (41) 41
toxicity (41) 41
pharmacology. drug treatments (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1055) 1055
Russian (13) 13
German (11) 11
French (8) 8
Korean (6) 6
Chinese (3) 3
Japanese (3) 3
Spanish (3) 3
Croatian (1) 1
Czech (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Incidence of osteonecrosis of the jaw (ONJ) in metastatic renal cell cancer patients (mRCC) treated with zoledronic acid (ZA)
by Gyergyay, Fruzsina and Nagyivanyi, Krisztian and Biro, Krisztina and Kuronya, Zsofia and Nemeth, Hajnalka and Geczi, Lajos
Journal of clinical oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20649 - e20649
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer
by Hiroyuki Tanakaa and Hiroaki Hiragab and Yoh Takekumac and Toru Harabayashid and Satoshi Nagamorid and Masayuki Endoa and Mitsuru Sugawarac and aDepartment of Pharmacy and bDepartment of Surgical Oncology and Hokkaido University and National Hospital Organization Hokkaido Cancer Center and Faculty of Pharmaceutical Sciences and cLaboratory of Pharmacokinetics and dDepartment of Urology
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2020, Volume 43, Issue 5, pp. 762 - 766
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib
by Sun Young Lee and and Na-ri Lee
The Korean journal of internal medicine, ISSN 1226-3303, 03/2018, Volume 33, Issue 2, p. 442
induced; Pazopanib | Leiomyosarcoma; Hyperthermia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
by Stacchiotti, Silvia and Mir, Olivier and Le Cesne, Axel and Vincenzi, Bruno and Fedenko, Alexander and Maki, Robert G and Somaiah, Neeta and Patel, Shreyaskumar and Brahmi, Mehedi and Blay, Jean Y and Boye, Kjetil and Sundby Hall, Kirsten and Gelderblom, Hans and Hindi, Nadia and Martin‐Broto, Javier and Kosela, Hanna and Rutkowski, Piotr and Italiano, Antoine and Duffaud, Florence and Kobayashi, Eisuke and Casali, Paolo G and Provenzano, Salvatore and Kawai, Akira
The oncologist (Dayton, Ohio), ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | Life Sciences & Biomedicine | Oncology | Science & Technology | Sarcomas | 25
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma
by Shiozawa, Kumiko and Shuting, Ji and Yoshioka, Yusuke and Ochiya, Takahiro and Kondo, Tadashi
Biochemical and biophysical research communications, ISSN 0006-291X, 01/2018, Volume 495, Issue 1, pp. 1322 - 1327
Extracellular vesicle | Synovial sarcoma | MiR-761 | Pazopanib-resistance | Biochemistry & Molecular Biology | Biophysics | Life Sciences & Biomedicine | Science & Technology | Proteins | Chemotherapy | MicroRNA | Analysis | Metastasis | Research institutes | Drug resistance | Lung cancer, Non-small cell | Pazopanib | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial
by Morgan, Robert D and Banerjee, Susana and Hall, Marcia and Clamp, Andrew R and Zhou, Cong and Hasan, Jurjees and Orbegoso, Cecilia and Taylor, Sarah and Tugwood, Jonathan and Lyon, Alexander R and Dive, Caroline and Rustin, Gordon J.S and Jayson, Gordon C
Gynecologic oncology, ISSN 0090-8258, 03/2020, Volume 156, Issue 3, pp. 545 - 551
Pazopanib | Fosbretabulin | Ovarian cancer | Relapse | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Solubility enhancement, solvent effect and thermodynamic analysis of pazopanib in co-solvent mixtures
by Shi, Hongwei and Xie, Yong and Xu, Jigui and Zhu, Jun and Wang, Cong and Wang, Hongyan
The Journal of chemical thermodynamics, ISSN 0021-9614, 04/2021, Volume 155
Solvent effect | Solubility | Co-solvency phenomenon | Thermodynamic properties | Pazopanib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase i and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
by Kerklaan, B. Milojkovic and Lolkema, M. P J and Devriese, L. A and Voest, E. E and Nol-Boekel, A and Mergui-Roelvink, M and Langenberg, M and Mykulowycz, K and Stoebenau, J and Lane, S and Legenne, P and Wissel, P and Smith, D. A and Giantonio, B. J and Schellens, J. H M and Witteveen, P. O
British journal of cancer, ISSN 0007-0920, 09/2015, Volume 113, Issue 5, p. 706
ovarian cancer | Cancer Research | Oncology | Pazopanib | topotecan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text HDAC inhibitors enhance the immunotherapy response of melanoma cells
by Booth, Laurence and Roberts, Jane L and Poklepovic, Andrew and Kirkwood, John and Dent, Paul
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 47, pp. 83155 - 83170
HDAC inhibitor | Autophagy | Immunotherapy | Pazopanib | Melanoma | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Biphenotypic siononasal sarcoma with acute exacerbation: A case report
by Okuda, Hiroshi and Kuze, Bunya and Shibata, Hirofumi and Hayashi, Hisamitsu and Nishihori, Takesumi and Mizuta, Keisuke and Kohyama, Keishi and Yasue, Yuji and Kato, Hisakazu and Aoki, Mitsuhiro
Otolaryngology case reports, ISSN 2468-5488, 09/2020, Volume 16, p. 100190
Biphenotypic sinonasal sarcoma | Chemotherapy | Ifosfamide | Doxorubicin | Pazopanib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)
by Parikh, Kaushal and Mandrekar, Sumithra J and Allen‐Ziegler, Katie and Esplin, Brandt and Tan, Angelina D and Marchello, Benjamin and Adjei, Alex A and Molina, Julian R
The oncologist (Dayton, Ohio), ISSN 1083-7159, 06/2020, Volume 25, Issue 6, pp. 523 - 531
Phase II | Malignant | Pleural mesothelioma | Pazopanib | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
by van der Graaf, Winette TA, Prof and Blay, Jean-Yves, Prof and Chawla, Sant P, MD and Kim, Dong-Wan, MD and Bui-Nguyen, Binh, MD and Casali, Paolo G, MD and Schöffski, Patrick, Prof and Aglietta, Massimo, MD and Staddon, Arthur P, MD and Beppu, Yasuo, MD and Le Cesne, Axel, MD and Gelderblom, Hans, Prof and Judson, Ian R, Prof and Araki, Nobuhito, MD and Ouali, Monia, MSc and Marreaud, Sandrine, MD and Hodge, Rachel, MSc and Dewji, Mohammed R, MSc and Coens, Corneel, MSc and Demetri, George D, MD and Fletcher, Christopher D, Prof and Dei Tos, Angelo Paolo, MD and Hohenberger, Peter, Prof and on behalf of the EORTC Soft Tissue and Bone Sarcoma Group and the PALETTE study group and EORTC Soft Tissue & Bone Sarcoma G and EORTC Soft Tissue and Bone Sarcoma Group and PALETTE study group
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Tumors | Sarcoma - secondary | Soft Tissue Neoplasms - mortality | Double-Blind Method | Soft Tissue Neoplasms - secondary | Humans | Middle Aged | Kaplan-Meier Estimate | Soft Tissue Neoplasms - drug therapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Sarcoma - drug therapy | Cross-Over Studies | Young Adult | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Sarcoma - mortality | Adult | Female | Aged | Complications and side effects | Dosage and administration | Sarcoma | Drug therapy | Pazopanib | Wound healing | Heart attacks | Mortality | Data collection | Clinical medicine | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS
by Verheijen, Remy B and Thijssen, Bas and Rosing, Hilde and Schellens, Jan H M and Nan, Lianda and Venekamp, Nikkie and Beijnen, Jos H and Steeghs, Neeltje and Huitema, Alwin D R
Therapeutic drug monitoring, ISSN 0163-4356, 04/2018, Volume 40, Issue 2, p. 230
LC-MS/MS | bioanalytical methods | pharmacokinetics | pazopanib | therapeutic drug monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
by Motzer, Robert J and Hutson, Thomas E and Cella, David and Reeves, James and Hawkins, Robert and Guo, Jun and Nathan, Paul and Staehler, Michael and de Souza, Paul and Merchan, Jaime R and Boleti, Ekaterini and Fife, Kate and Jin, Jie and Jones, Robert and Uemura, Hirotsugu and De Giorgi, Ugo and Harmenberg, Ulrika and Wang, Jinwan and Sternberg, Cora N and Deen, Keith and McCann, Lauren and Hackshaw, Michelle D and Crescenzo, Rocco and Pandite, Lini N and Choueiri, Toni K
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 722 - 731
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the urinary system | General aspects | Kidneys | Nephrology. Urinary tract diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Double-Blind Method | Humans | Kaplan-Meier Estimate | Male | Disease-Free Survival | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Quality of Life | Sulfonamides - adverse effects | Adult | Female | Indoles - therapeutic use | Kidney Neoplasms - pathology | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antimitotic agents | Carcinoma, Renal cell | Research | Drug therapy | Comparative analysis | Antineoplastic agents | Pazopanib | Thrombocytopenia | Medical research | Alanine | Cell survival | Fatigue | Pharynx | Patients | Feet | Quality of life | Metastases | Alanine transaminase | Interferon | Safety | Drug dosages | Clear cell-type renal cell carcinoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
by Albiges, Laurence and Powles, Tom and Staehler, Michael and Bensalah, Karim and Giles, Rachel H and Hora, Milan and Kuczyk, Markus A and Lam, Thomas B and Ljungberg, Börje and Marconi, Lorenzo and Merseburger, Axel S and Volpe, Alessandro and Abu-Ghanem, Yasmin and Dabestani, Saeed and Fernández-Pello, Sergio and Hofmann, Fabian and Kuusk, Teele and Tahbaz, Rana and Bex, Axel
European urology, ISSN 0302-2838, 08/2019, Volume 76, Issue 2, pp. 151 - 156
Sunitinib | Cabozantinib | Renal cell carcinoma | Ipilimumab | Nivolumab | Metastatic | Immune checkpoint inhibitors | Pazopanib | Guidelines | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Antimitotic agents | Care and treatment | Carcinoma, Renal cell | Metastasis | Antineoplastic agents | Index Medicus | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights